| Market Cap | 30.26M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -1.5M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 8.00% |
| Sales | 4.39M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -22.00% |
| Dividend | N/A | Price/Book | 1.50 | EPS next 5Y | - | 52W High Chg | -52.00% |
| Recommedations | - | Quick Ratio | 8.84 | Shares Outstanding | 6.42B | 52W Low Chg | 10.00% |
| Insider Own | 49.07% | ROA | -5.16% | Shares Float | 3.49B | Beta | 1.15 |
| Inst Own | - | ROE | -8.12% | Shares Shorted/Prior | -/- | Price | 0.00451 |
| Gross Margin | 31.44% | Profit Margin | -34.15% | Avg. Volume | 1,211 | Target Price | - |
| Oper. Margin | -33.80% | Earnings Date | Feb 27 | Volume | 100 | Change | 0.00% |
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.